BiotechTube
Arisan Therapeutics

Arisan Therapeutics

San Diego, United States· Est.
arisanthera.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Arisan Therapeutics is a private, preclinical-stage biotech focused on developing small-molecule antiviral drugs for infectious diseases. The company is targeting high-burden viral infections such as COVID-19 and influenza, operating in a critical and dynamic segment of the pharmaceutical market. As a young company, it is in the early stages of building its pipeline and technology platform, positioning itself to address unmet medical needs in virology. Its success will depend on advancing its research, securing funding, and navigating the complex competitive and regulatory landscape of antiviral drug development.

Infectious DiseasesVirology

Technology Platform

Small-molecule drug discovery for antiviral therapeutics.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The enduring need for next-generation oral antivirals for COVID-19 and influenza presents a significant commercial opportunity.
Growing global focus on pandemic preparedness may increase funding and partnership interest in novel antiviral platforms.

Risk Factors

High scientific risk of preclinical failure, intense competition from large pharmaceutical companies, and a challenging biotech funding environment threaten the company's viability.
The commercial market for COVID-19 therapeutics is volatile and may contract.

Competitive Landscape

The antiviral space is highly competitive, dominated by large players like Pfizer (Paxlovid), Merck (Lagevrio), Roche, and Gilead. Numerous biotechs are also pursuing novel mechanisms for COVID-19, influenza, and other viruses, making differentiation critical.

More companies in Small Molecule Drugs →More companies in United States →